<SEC-DOCUMENT>0001104659-21-011590.txt : 20210203
<SEC-HEADER>0001104659-21-011590.hdr.sgml : 20210203
<ACCEPTANCE-DATETIME>20210203164217
ACCESSION NUMBER:		0001104659-21-011590
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20210203
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20210203
DATE AS OF CHANGE:		20210203

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RHYTHM PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001649904
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				462159271
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38223
		FILM NUMBER:		21586746

	BUSINESS ADDRESS:	
		STREET 1:		222 BERKELEY STREET
		STREET 2:		12TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		857-264-4280

	MAIL ADDRESS:	
		STREET 1:		222 BERKELEY STREET
		STREET 2:		12TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RHYTHM METABOLIC, INC.
		DATE OF NAME CHANGE:	20150803
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm213890d3_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:rytm="http://rhythmtx.com/20210202">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_rytm_rhythmtx.com_20210202 -->
<!-- Field: Set; Name: xdx; ID: xdx_047_20210203_20210203 -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DEntityCentralIndexKey_0001649904 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
  <ix:hidden>
    <ix:nonNumeric contextRef="From2021-02-03to2021-02-03" name="dei:EntityCentralIndexKey">0001649904</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2021-02-03to2021-02-03" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    </ix:hidden>
  <ix:references>
    <link:schemaRef xlink:href="rytm-20210202.xsd" xlink:type="simple" />
    </ix:references>
  <ix:resources>
    <xbrli:context id="From2021-02-03to2021-02-03">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001649904</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-03</xbrli:startDate>
        <xbrli:endDate>2021-02-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    </ix:resources>
  </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<p style="margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM&#160;<span id="xdx_903_edei--DocumentType_c20210203__20210203_zez3y2C4VV7l"><ix:nonNumeric contextRef="From2021-02-03to2021-02-03" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section&#160;13 or 15(d)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of report (Date of earliest event
reported): <span id="xdx_90D_edei--DocumentPeriodEndDate_c20210203__20210203_ziloFiFDAhfh"><ix:nonNumeric contextRef="From2021-02-03to2021-02-03" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">February 3, 2021</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_90B_edei--EntityRegistrantName_c20210203__20210203_zWn1DQsMS4Zh"><b><ix:nonNumeric contextRef="From2021-02-03to2021-02-03" name="dei:EntityRegistrantName">RHYTHM
PHARMACEUTICALS, INC.</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified
in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: top; width: 34%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_905_edei--EntityIncorporationStateCountryCode_c20210203__20210203_z7CyJJJ6aouf"><ix:nonNumeric contextRef="From2021-02-03to2021-02-03" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 32%; text-align: center"><span id="xdx_90F_edei--EntityFileNumber_c20210203__20210203_zzI0RMIrFHpd" style="font-size: 10pt"><b><ix:nonNumeric contextRef="From2021-02-03to2021-02-03" name="dei:EntityFileNumber">001-38223</ix:nonNumeric></b></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 32%; text-align: center"><span id="xdx_909_edei--EntityTaxIdentificationNumber_c20210203__20210203_z4WXv0DrZXlk" style="font-size: 10pt"><b><ix:nonNumeric contextRef="From2021-02-03to2021-02-03" name="dei:EntityTaxIdentificationNumber">46-2159271</ix:nonNumeric></b></span></td></tr>
<tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(State or other jurisdiction<br />
    of incorporation or organization)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(Commission<br />
    File Number)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(I.R.S. Employer<br />
    Identification No.)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_90D_edei--EntityAddressAddressLine1_c20210203__20210203_zhryLD9bnHQf"><b><ix:nonNumeric contextRef="From2021-02-03to2021-02-03" name="dei:EntityAddressAddressLine1">222
Berkeley Street</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_908_edei--EntityAddressAddressLine2_c20210203__20210203_zos9v72H4dQ4"><b><ix:nonNumeric contextRef="From2021-02-03to2021-02-03" name="dei:EntityAddressAddressLine2">12th
Floor</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_902_edei--EntityAddressCityOrTown_c20210203__20210203_zde5Br8TYWoi"><b><ix:nonNumeric contextRef="From2021-02-03to2021-02-03" name="dei:EntityAddressCityOrTown">Boston</ix:nonNumeric></b></span><b>,
<span id="xdx_905_edei--EntityAddressStateOrProvince_c20210203__20210203_z1mrFz0vvfU"><ix:nonNumeric contextRef="From2021-02-03to2021-02-03" name="dei:EntityAddressStateOrProvince">MA</ix:nonNumeric></span></b><b> <span id="xdx_902_edei--EntityAddressPostalZipCode_c20210203__20210203_zvMYDPmHzWGi"><ix:nonNumeric contextRef="From2021-02-03to2021-02-03" name="dei:EntityAddressPostalZipCode">02116</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)
(Zip Code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>(<span id="xdx_90A_edei--CityAreaCode_c20210203__20210203_zq1YaNnRlInc"><ix:nonNumeric contextRef="From2021-02-03to2021-02-03" name="dei:CityAreaCode">857</ix:nonNumeric></span></b><b>)
<span id="xdx_906_edei--LocalPhoneNumber_c20210203__20210203_zdvIb7YnzbHl"><ix:nonNumeric contextRef="From2021-02-03to2021-02-03" name="dei:LocalPhoneNumber">264-4280</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number, include
area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>N/A</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">(Former Name or Former
Address, if Changed Since Last Report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Check the appropriate box below if the Form&#160;8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span id="xdx_908_edei--WrittenCommunications_c20210203__20210203_zauzP2aabtyk" style="font-family: Wingdings"><ix:nonNumeric contextRef="From2021-02-03to2021-02-03" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span id="xdx_901_edei--SolicitingMaterial_c20210203__20210203_zhf0Yy5NpQh9" style="font-family: Wingdings"><ix:nonNumeric contextRef="From2021-02-03to2021-02-03" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span id="xdx_90C_edei--PreCommencementTenderOffer_c20210203__20210203_zDGYgLCRca0i" style="font-family: Wingdings"><ix:nonNumeric contextRef="From2021-02-03to2021-02-03" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span id="xdx_904_edei--PreCommencementIssuerTenderOffer_c20210203__20210203_zHSjsldiKhM5" style="font-family: Wingdings"><ix:nonNumeric contextRef="From2021-02-03to2021-02-03" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; padding: 3pt; text-align: center; text-indent: 3pt; width: 33%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Title
    of each class</b></span></td>
    <td style="width: 1%"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; padding: 3pt; text-align: center; text-indent: 3pt; width: 32%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Trading
    Symbol(s)</b></span></td>
    <td style="width: 1%"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; padding: 3pt; text-align: center; text-indent: 3pt; width: 33%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name
    of each exchange on which registered</b></span></td></tr>
<tr style="vertical-align: top">
    <td style="padding: 3pt; text-align: center; text-indent: 3pt"><span id="xdx_909_edei--Security12bTitle_c20210203__20210203_zpl2qIwhsi1k" style="font: 10pt Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2021-02-03to2021-02-03" name="dei:Security12bTitle">Common
    Stock, $0.001 par value per share</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="padding: 3pt; text-align: center; text-indent: 3pt"><span id="xdx_907_edei--TradingSymbol_c20210203__20210203_zN2w09LO6MQ8" style="font: 10pt Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2021-02-03to2021-02-03" name="dei:TradingSymbol">RYTM</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="padding: 3pt; text-align: center; text-indent: 3pt"><span id="xdx_904_edei--SecurityExchangeName_c20210203__20210203_z4bIngbyzjL5" style="font: 10pt Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2021-02-03to2021-02-03" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The
    Nasdaq Stock Market LLC</ix:nonNumeric></span> <span style="font: 10pt Times New Roman, Times, Serif">(Nasdaq Global Market)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2
of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Emerging growth company <span id="xdx_909_edei--EntityEmergingGrowthCompany_c20210203__20210203_zw2fmVh5QaA8" style="font-family: Wingdings"><ix:nonNumeric contextRef="From2021-02-03to2021-02-03" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;&#160;<span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 2.02 Results of Operations and Financial Condition.&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information under the heading
 &#8220;Preliminary Financial Information&#8221; set forth under Item 8.01 of this Current Report on Form 8-K (the &#8220;Current
Report&#8221;) is incorporated by reference into this Item 2.02.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item&#160;8.01 Other Events.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Rhythm Pharmaceuticals, Inc. (&#8220;we&#8221;, &#8220;our&#8221;
and &#8220;us&#8221;) is providing the following business update:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Recent Developments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Phase 2 Basket Study</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On January 26, 2021, we announced new
proof-of-concept interim data from our ongoing Phase 2 Basket Study across individuals with one of three distinct rare
genetic diseases of obesity: HET obesity due to a genetic variant in one of the two alleles of the <i>POMC</i>, <i>PCSK1</i>
or <i>LEPR</i> gene, or HETs; obesity due to <i>SRC1</i> deficiency; and obesity due to S<i>H2B1</i> deficiency. Across five
cohorts, 65 patients with severe obesity were eligible for analysis as of a cutoff date of December 17, 2020. Twelve of these
patients had failed bariatric surgery. The primary endpoint of the study is the percent of patients in each subgroup
showing at least a 5 percent loss of body weight over three months.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">HET obesity (<i>POMC, PCSK1, LEPR</i>) highlights include,
as of the cutoff date:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 0.2in">&#160;</td>
    <td style="text-align: center; width: 0.2in"><span style="font-family: Symbol">&#183;</span></td>
    <td>Overall, 12 of 35 patients (34.3 percent) achieved the primary endpoint; this full analysis includes six patients who
    withdrew early;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Symbol">&#183;</span></td>
    <td>Mean reduction from baseline in body weight across all 35 patients was -3.7 percent, which includes both clinical responders
    and non-responders;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Symbol">&#183;</span></td>
    <td>Among the 12 patients who achieved the primary endpoint (responder group), the mean reduction from baseline in body weight
    was -10.1 percent;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Symbol">&#183;</span></td>
    <td>Patients with HET obesity were stratified into three pre-specified cohorts by classification of their genetic variants
    according to American College of Medical Genetics guidelines:</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 0.8in">&#160;</td>
    <td style="vertical-align: top; text-align: center; width: 0.2in"><span style="font-family: Symbol">&#111;</span></td>
    <td>Four of eight patients (50.0 percent) with a pathogenic or likely pathogenic variant achieved greater than 5 percent weight
    loss;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Symbol">&#111;</span></td>
    <td>Four of eight patients (50.0 percent) with the N221D variant of the <i>PCSK1</i> gene achieved greater than 5 percent
    weight loss;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Symbol">&#111;</span></td>
    <td>Four of 19 patients (21.1 percent) with a variant of unknown significance achieved greater than 5 percent weight loss.</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Data from the SRC1 and SH2B1 cohorts were based on an interim
analysis of patients who completed 12 weeks of therapy. This analysis did not include 15 patients who withdrew early due to COVID-related
issues, adverse events or were lost to follow-up. Also not included were data from 12 patients who remain ongoing but have not
yet reached 12 weeks of therapy. A majority of the patients who withdrew early experienced weight loss. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Obesity due to SRC1 deficiency highlights include, as of the
cutoff date:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 0.2in">&#160;</td>
    <td style="text-align: center; width: 0.2in"><span style="font-family: Symbol">&#183;</span></td>
    <td>Four of 13 patients (30.8 percent) achieved the primary endpoint;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Symbol">&#183;</span></td>
    <td>Mean reduction from baseline in body weight across all 13 patients was -3.7 percent, which included both clinical responders
    and non-responders;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Symbol">&#183;</span></td>
    <td>Among the four patients who achieved the primary endpoint (responder group) the mean reduction from baseline in body weight
    was -8.4 percent.</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Obesity due to SH2B1 deficiency highlights include, as of the
cutoff date:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 0.2in">&#160;</td>
    <td style="text-align: center; width: 0.2in"><span style="font-family: Symbol">&#183;</span></td>
    <td>Nine of 17 patients (52.9 percent) achieved greater than 5 percent weight loss over 12 weeks of therapy;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Symbol">&#183;</span></td>
    <td>Mean reduction from baseline in body weight across all 17 patients was -3.9 percent, which included clinical responders
    and non-responders;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Symbol">&#183;</span></td>
    <td>Among the nine patients who achieved the primary endpoint (responder group), the mean reduction from baseline in body
    weight was -7.1 percent.</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Consistent with prior clinical experience,
setmelanotide was generally well tolerated in each of these rare genetic diseases of obesity. The most common treatment-emergent
adverse events included mild injection site reactions, hyperpigmentation, and nausea and vomiting, which occurred early in the
treatment course. There were no serious adverse events related to treatment with setmelanotide.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are in discussions with the FDA to define
a potential path for setmelanotide towards registration for these indications. Pending the outcome of these discussions, we plan
to initiate a pivotal Phase 3 trial evaluating setmelanotide in patients with HET obesity and <i>SRC1</i> and <i>SH2B1</i> deficiency
obesities in the second half of 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Pivotal Phase 3 Clinical Trial in Bardet-Biedl Syndrome
and Alstr&#246;m Syndrome</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In December 2020, we announced positive
topline results from a pivotal Phase 3 clinical trial evaluating setmelanotide for the treatment of insatiable hunger and severe obesity
in individuals with Bardet-Biedl syndrome, or BBS, or Alstr&#246;m syndrome. The trial met its primary and all key secondary endpoints,
showing statistically significant and clinically meaningful reductions in weight and hunger scores. All primary endpoint responders
were patients with BBS. There were three evaluable patients with Alstr&#246;m syndrome and none of them met the primary endpoint.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Thirty-two individuals with BBS and six
individuals with Alstr&#246;m syndrome were enrolled in the pivotal cohort for this Phase 3 trial. The primary analysis was conducted
on 31 evaluable participants (28 with BBS and three with Alstr&#246;m syndrome) 12 years old and older. Five study participants
(three with BBS and two with Alstr&#246;m syndrome) were younger than 12 years old at enrollment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Eleven of 31, or 34.5 percent, of participants
achieved the primary endpoint of at least 10 percent reduction in body weight from baseline at approximately 52 weeks of therapy
(p=0.0024). Eleven of 28 patients with BBS achieved 10 percent reduction in body weight and no patients with Alstr&#246;m syndrome
achieved 10 percent reduction in body weight.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Key secondary endpoints included additional
weight loss and hunger reduction analyses. Mean reduction from baseline in body weight was -6.2 percent (p&lt;0.0001). Mean reduction
from baseline in most hunger rating was -30.8 percent (p&lt;0.0001) and 60.2 percent of participants achieved at least 25 percent
reduction in most hunger scores from baseline at approximately 52 weeks of therapy (p&lt;0.0001).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Consistent with prior clinical experience,
setmelanotide was observed to be generally well tolerated. Treatment-emergent adverse events included mild injection site reactions
and nausea with infrequent vomiting. There were no serious adverse events related to treatment with setmelanotide. Eight patients discontinued
from study drug treatment during the trial, five due to adverse events (one on placebo at the time), and three for other reasons
(one on placebo at the time).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We plan to complete regulatory submissions
to both the FDA and the European Medicines Association for BBS in the second half of 2021. We expect to determine the next steps
for Alstr&#246;m syndrome upon completing a full analysis of the final data from this trial in the first half of 2021. We anticipate
sharing the full data from this Phase 3 clinical trial in a forthcoming publication or in a presentation at an upcoming medical
meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>BMI-Z Data from Phase 3 Clinical Trials</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On January 26, 2021, we presented new,
predefined, exploratory endpoint data from our Phase 3 clinical trial in patients with BBS and AS, showing the results of setmelanotide
on BMI-Z scores for patients younger than 18 years old with BBS. The BMI-Z score, or BMI standard deviation score, represents
the number of standard deviations from median BMI by child age and sex, and measures relative weight adjusted for a child&#8217;s
age and sex.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In 16 patients younger than 18 with BBS,
setmelanotide was associated with statistically significant and clinically meaningful reductions in BMI-Z scores. In these patients,
the mean BMI-Z score was reduced from 3.74 at baseline to 2.98 for a reduction of -0.76, or -24.5 percent (p=0.0006).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We had also evaluated BMI Z-scores in
our previous pivotal trials as a predefined, exploratory endpoint. In six patients younger than 19 with <i>POMC</i>
deficiency obesity, the mean BMI-Z score was reduced from 3.35 at baseline to 1.73 for a reduction of -1.6, or -49.2%
(p=0.007). In three patients younger than 19 with <i>LEPR</i> deficiency obesity, the mean BMI-Z score was reduced from 3.52
at baseline to 3.03 for a reduction of -0.49, or -13.4% (p=0.012).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Updated U.S. Prevalence Estimates for Basket Study Indications</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have increased our internal database
of sequencing samples to approximately 37,500. We are using these data to support our research, patient finding and community
building efforts in order to better understand rare genetic diseases of obesity. Our genetic sequencing results demonstrated that
approximately 10 to 15 percent of obese individuals sampled as of September 30, 2020, showed a relevant MC4R pathway genotype
in the <i>POMC, PCSK1, </i>and <i>LEPR</i> HETs and <i>SRC1</i> or <i>SH2B1</i> genes. We estimate, based on a combination of
these sequencing yields, as well as clinical data on setmelanotide response rates among patients with variants in these genes,
that there are 100,000 to 200,000 potentially setmelanotide-responsive patients in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Exploratory Basket Study in an Additional 31 MC4R Pathway
Genes</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On January 26, 2021, we presented new data
generated from our proprietary gene curation and selection strategy, which is designed to evaluate a gene&#8217;s relevance to
the MC4R pathway with the goal of identifying genetic patient populations with the potential to benefit from setmelanotide therapy.
Using this proprietary approach, we identified an additional 31 MC4R pathway genes with strong or very strong pathway relevance.
Pending discussions with the FDA, we plan to initiate a new exploratory MC4R pathway basket trial in patients with these 31 new
genes in the second half of 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Other Clinical Updates</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the first half of 2021, we plan to initiate
a Phase 2 clinical trial in hypothalamic obesity, initiate a potentially registrational clinical trial of the weekly formulation
of setmelanotide, and announce data from a Phase 2 basket study in MC4R-recusable patients. In the second half of 2021, we plan to initiate
a clinical trial of setmelanotide in pediatric patients aged two to six and expect to receive a decision from the EMA on our MAA
for setmelanotide to treat individuals living with <i>POMC</i> or <i>LEPR</i> deficiency obesities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>PRV Transfer</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On January 5, 2021, we entered into an
asset purchase agreement with Alexion Pharmaceuticals, Inc., or Alexion, pursuant to which we agreed to sell our Rare Pediatric
Disease Priority Review Voucher, PRV, to Alexion, or the PRV Transfer. We were awarded the voucher under a FDA program intended
to encourage the development of certain rare pediatric disease product applications. We received the PRV when IMCIVREE was approved
by the FDA. Pursuant to the transfer agreement, Alexion agreed to pay us $100 million in cash upon the closing of the sale. The
transaction remains subject to customary closing conditions, including the expiration or termination of the applicable waiting
period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Preliminary Financial Information </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our audited financial statements for the
year ended December 31, 2020 will not be available until after this offering is completed and consequently will not be available
to you prior to investing in this offering. Based upon preliminary estimates and information available to us as of the date of
this prospectus supplement, we expect to report that we had approximately $173.0 million of cash, cash equivalents and short-term
investments as of December 31, 2020. Based on our current plans, we believe our existing cash, cash equivalents and short term-investments
and the expected proceeds from the PRV Transfer will be sufficient to fund our operations into the second half of 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have not yet completed our financial
close process for the year ended December 31, 2020. This estimate of our cash, cash equivalents and short-term investments as
of December 31, 2020 is preliminary and is subject to change upon completion of our financial statement closing procedures. There
can be no assurance that our final cash position as of December 31, 2020 will not differ from these estimates, including as a
result of review adjustments and any such changes could be material. Our independent registered public accountants have not audited,
reviewed or performed any procedures with respect to such preliminary financial data and accordingly do not express an opinion
or any other form of assurance with respect thereto. These results could change as a result of further review. <span style="background-color: white">Complete
results will be included in our Annual Report on&#160;Form&#160;10-K&#160;for the year ended December&#160;31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to the Development of Setmelanotide</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>The number of patients suffering from each of the MC4R
pathway deficiencies we are targeting is small and has not been established with precision. If the actual number of patients is
smaller than we estimate, our revenue and ability to achieve profitability may be materially adversely affected.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Due to the rarity of our target indications,
there is no comprehensive patient registry or other method of establishing with precision the actual number of patients with MC4R
pathway deficiencies. As a result, we have had to rely on other available sources to derive clinical prevalence estimates for
our target indications. In addition, we have internal genetic sequencing results from approximately 37,500 patients, as of September
30, 2020, with severe obesity that provide another approach to estimating prevalence. Since the published epidemiology studies
for these genetic deficiencies are based on relatively small population samples, and are not amenable to robust statistical analyses,
it is possible that these projections may significantly exceed the addressable population, particularly given the need to genotype
patients to definitively confirm a diagnosis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Based on multiple epidemiological methods, we have
estimated the potential addressable patient populations with these MC4R pathway deficiencies based on the following sources and
assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 0.2in">&#160;</td>
    <td style="text-align: center; width: 0.2in"><span style="font-family: Symbol">&#183;</span></td>
    <td><i>POMC Deficiency Obesity</i>. POMC Deficiency Obesity is defined by the presence of biallelic variants in the POMC or
    PCSK1 genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VOUS). Our addressable
    patient population estimate for POMC deficiency obesity is approximately 100 to 500 patients in the United States, with a
    comparable addressable patient population in Europe. Our estimates are based on:</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 0.4in">&#160;</td>
    <td style="width: 0.2in"><span style="font-family: Symbol">&#183;</span></td>
    <td>approximately 50 patients with POMC deficiency obesity noted in a series of published case reports, each mostly reporting
    a single or small number of patients. However, we believe our addressable patient population for this deficiency may be approximately
    100 to 500 patients in the United States, and a comparable addressable patient population in Europe, as most of the reported
    cases are from a small number of academic research centers, and because genetic testing for POMC deficiency obesity is often
    unavailable and currently is rarely performed;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td><span style="font-family: Symbol">&#183;</span></td>
    <td>our belief, based on discussions with experts in rare diseases, that the number of diagnosed cases could increase several&#45;fold
    with increased awareness of this deficiency and the availability of new treatments;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td><span style="font-family: Symbol">&#183;</span></td>
    <td>U.S. Census Bureau figures for adults and children, and Centers for Disease Control and Prevention, or CDC, prevalence
    numbers for severe adult obese patients (body mass index, or BMI, greater than 40 kg/m<sup>2</sup>) and for severe early onset
    obese children (99th percentile at ages two to 17 years old); and</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td><span style="font-family: Symbol">&#183;</span></td>
    <td>our internal sequencing yield for POMC deficiency obesity patients (including both POMC and PCSK1 gene disorders), defined as patients having biallelic variants in the POMC or PCSK1 genes that are interpreted
    as pathogenic, likely pathogenic, or of uncertain significance (VOUS), of approximately 0.05%.</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 0.2in">&#160;</td>
    <td style="text-align: center; width: 0.2in"><span style="font-family: Symbol">&#183;</span></td>
    <td><i>LEPR Deficiency Obesity</i>. LEPR Deficiency Obesity is defined by the presence of biallelic variants in the LEPR gene
    that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VOUS). Our addressable patient
    population estimate for LEPR deficiency obesity is approximately 500 to 2,000 patients in the United States, with a
    comparable addressable patient population in Europe. Our estimates are based on:</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 0.4in">&#160;</td>
    <td style="width: 0.2in"><span style="font-family: Symbol">&#183;</span></td>
    <td>epidemiology studies on LEPR deficiency obesity in small cohorts of patients comprised of children with severe obesity
    and adults with severe obesity who have a history of early onset obesity;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td><span style="font-family: Symbol">&#183;</span></td>
    <td>U.S. Census Bureau figures for adults and children and CDC prevalence numbers for severe adult obese patients (BMI, greater
    than 40 kg/m<sup>2</sup>) and for severe early onset obese children (99th percentile at ages two to 17 years old);</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td><span style="font-family: Symbol">&#183;</span></td>
    <td>with wider availability of genetic testing expected for LEPR deficiency obesity and increased awareness of new treatments,
    our belief that up to 40% of patients with these disorders may eventually be diagnosed; and</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td><span style="font-family: Symbol">&#183;</span></td>
    <td>our internal sequencing yield for LEPR deficiency obesity patients, defined as patients having biallelic variants in the
    LEPR gene that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VOUS), of approximately 0.09%.</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 0.2in">&#160;</td>
    <td style="text-align: center; width: 0.2in"><span style="font-family: Symbol">&#183;</span></td>
    <td><i>Bardet&#45;Biedl Syndrome</i>. Our addressable patient population estimate for BBS is approximately 1,500 to 2,500
    patients in the United States based on:</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 0.4in">&#160;</td>
    <td style="width: 0.2in"><span style="font-family: Symbol">&#183;</span></td>
    <td>published prevalence estimates of one in 100,000 in North America, which projects to approximately 3,250 people in the
    United States. We believe the majority of these patients are addressable patients; and</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td><span style="font-family: Symbol">&#183;</span></td>
    <td>our belief that with wider availability of genetic testing expected for BBS and increased awareness of new treatments,
    the number of patients diagnosed with this disorder will increase.</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 0.2in">&#160;</td>
    <td style="text-align: center; width: 0.2in"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: left"><i>Alstr&#246;m Syndrome</i>. Our addressable patient population estimate for Alstr&#246;m syndrome is approximately
    1,000 patients worldwide and approximately 500 patients in the United States. This estimate is based on:</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 0.4in">&#160;</td>
    <td style="width: 0.2in"><span style="font-family: Symbol">&#183;</span></td>
    <td>published prevalence estimates of one in 1,000,000 in North America, which projects to approximately 325 people in the
    United States. We believe the majority of these patients are addressable patients; and</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td><span style="font-family: Symbol">&#183;</span></td>
    <td>our belief that with wider availability of genetic testing expected for Alstr&#246;m syndrome and increased awareness
    of new treatments, the number of patients diagnosed with this disorder will increase.</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 0.2in">&#160;</td>
    <td style="text-align: center; width: 0.2in"><span style="font-family: Symbol">&#183;</span></td>
    <td><i>POMC, PCSK1, or LEPR Heterozygous Deficiency Obesities; SRC1 and SH2B1 Deficiency Obesities</i>. Our potential setmelanotide-responsive
    patient population estimate for POMC, PCSK1, or LEPR heterozygous, SRC1 and SH2B1 deficiency obesity patients with at least
    one variant interpreted as pathogenic, likely pathogenic, or of uncertain significance (VOUS) is 100,000 to 200,000 patients
    in the United States. Our estimates are
    based on:</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 0.4in">&#160;</td>
    <td style="vertical-align: top; text-align: left; width: 0.2in"><span style="font-family: Symbol">&#183;</span></td>
    <td>U.S. Census Bureau figures for adults and children and CDC prevalence numbers for severe adult obese patients (BMI greater
    than 40 kg/m<sup>2</sup>) and for severe early onset obese children (99th percentile at ages two to 17 years old); </td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Symbol">&#183;</span></td>
    <td>our internal sequencing yield of patients with POMC, PCSK1, or LEPR heterozygous, SRC1 or SH2B1 variants interpreted as
    pathogenic, likely pathogenic, or of uncertain significance (VOUS)of approximately 10-15%; and</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Symbol">&#183;</span></td>
    <td>a clinical response rate of 40% for patients carrying pathogenic or likely pathogenic variants, and 20% for patients carrying
    a variant of uncertain significance (VOUS).</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The clinical response rate used in this
calculation is based on the clinical data currently available to us from our trials and may change as more data become available.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 0.2in">&#160;</td>
    <td style="text-align: center; width: 0.2in"><span style="font-family: Symbol">&#183;</span></td>
    <td><i>MC4R Deficiency Obesity</i>. Our addressable patient population estimate for MC4R deficiency obesity is approximately
    greater than 10,000 patients in the United States. This estimate is based on:</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 0.4in">&#160;</td>
    <td style="vertical-align: top; text-align: left; width: 0.2in"><span style="font-family: Symbol">&#183;</span></td>
    <td>U.S. Census Bureau figures for adults and children and CDC prevalence numbers for severe adult obese patients (BMI, greater
    than 40 kg/m<sup>2</sup>) and for severe early onset obese children (99th percentile at ages two to 17 years old); and</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Symbol">&#183;</span></td>
    <td>our internal sequencing yield for MC4R deficiency obesity patients of approximately 2.0% prior to application of functional
    filters.</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 0.2in">&#160;</td>
    <td style="text-align: center; width: 0.2in"><span style="font-family: Symbol">&#183;</span></td>
    <td><i>Smith&#45;Magenis Syndrome</i>. Our addressable patient population estimate for Smith&#45;Magenis syndrome is approximately
    greater than 2,400 patients in the United States. This estimate is based on:</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 0.4in">&#160;</td>
    <td style="vertical-align: top; text-align: left; width: 0.2in"><span style="font-family: Symbol">&#183;</span></td>
    <td>published prevalence estimates of one in 25,000 in the United States, which projects to approximately 13,000 people in
    the United States;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Symbol">&#183;</span></td>
    <td>published prevalence estimates that approximately 10% of patients with Smith&#45;Magenis syndrome have RAI1 variants that
    may affect the MC4R pathway and 90% of patients with Smith&#45;Magenis syndrome have 17p11.2 chromosomal deletions which also
    may affect the MC4R pathway, of which approximately 67% and 13%, respectively, live with obesity; and</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Symbol">&#183;</span></td>
    <td>U.S. Census Bureau figures for total population of adults and children.</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe that the patient populations
in the European Union, or EU, are at least as large as those in the United States. However, we do not have comparable epidemiological
data from the EU and these estimates are therefore based solely on applying relative population percentages to the company&#45;derived
estimates described above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Defining the exact genetic variants that
result in MC4R pathway disorders is complex, so if any approval that we obtain is based on a narrower definition of these patient
populations than we had anticipated, then the potential market for setmelanotide for these indications will be smaller than we
originally believed. In either case, a smaller patient population in our target indications would have a materially adverse effect
on our ability to achieve commercialization and generate revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Our approach to treating patients with MC4R pathway
deficiencies requires the identification of patients with unique genetic subtypes, for example, POMC genetic deficiency. The
FDA or other equivalent competent authorities in foreign jurisdictions could require the clearance, approval or CE marking of
an in vitro companion diagnostic device to ensure appropriate selection of patients as a condition of approving setmelanotide
in additional indications. The requirement that we obtain clearance, approval or CE mark of an in vitro companion diagnostic device will require
substantial financial resources, and could delay or prevent the receipt of additional regulatory approvals for setmelanotide,
or adversely affect those we have already obtained.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have focused our development of
setmelanotide as a treatment for obesity caused by certain genetic deficiencies affecting the MC4R pathway. To date, we have
employed <i>in vitro</i> genetic diagnostic testing to select patients for enrollment in our clinical trials, including our
clinical trials for IMCIVREE and for other potential indications for setmelanotide. If the safe and effective use of any of
our product candidates depends on an <i>in vitro</i> diagnostic that is not otherwise commercially available, then the FDA
may require approval or clearance of that diagnostic, known as a companion diagnostic, at the same time as, or in connection
with, the FDA approval of such product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the FDA or a comparable regulatory
authority requires clearance or approval of a companion diagnostic for setmelanotide, any delay or failure by us or our
current and future collaborators to develop or obtain regulatory clearance or approval of, or to CE mark, such tests, if
necessary, could delay or prevent us from obtaining additional approvals for setmelanotide, or adversely affect the approvals
we have already obtained. For example, in November 2020, FDA approved IMCIVREE for chronic weight management in adult and
pediatric patients 6 years of age and older with obesity due to POMC, PCSK1, or LEPR deficiencies confirmed by genetic
testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of
uncertain significance. Although the FDA did not require that we obtain approval of a companion diagnostic prior to approving
the New Drug Application, or NDA, for IMCIVREE, in connection with the NDA approval we agreed as a post-marketing commitment
to conduct adequate analytical and clinical validation testing to develop and establish an <i>in-vitro</i> companion
diagnostic device to accurately and reliably detect patients with variants in the POMC, PCSK1, and LEPR genes that may
benefit from setmelanotide therapy. In September 2020, our collaboration partner, Prevention Genetics, submitted a de novo
request seeking FDA authorization to market such an <i>in-vitro</i> companion diagnostic device for IMCIVREE as a Class II
medical device. In December 2020, the FDA sent Prevention Genetics a major deficiency letter in response to the de novo
request, which among other things, placed the review on hold and requested additional information needed to support the
requested device classification. Although we believe that Prevention Genetics will be able to resolve the issues identified
in the major deficiency letter, they may be unsuccessful in doing so, and Prevention Genetics may be required to submit and
obtain approval of a PMA application for the <i>in-vitro</i> companion diagnostic device before we are able to fulfill our
post-marketing commitment to FDA, which would lead to further delay and could entail significant additional expense. If we
are unable to fulfill our postmarket commitments for IMCIVREE in a timely manner, the FDA could take enforcement action
against us, which could adversely affect our prospects. Further, if the FDA or a comparable regulatory authority requires clearance or approval of a companion diagnostic when we seek additional
approvals for setmelanotide, any delay or failure by us or our current and future collaborators to develop or obtain regulatory clearance
or approval of, or to CE mark, such tests, if necessary, could delay or prevent us from obtaining such additional approvals for setmelanotide,
or adversely affect the approvals we have already obtained.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Forward-Looking Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Current Report contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current
Report that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation
statements regarding the sufficiency of our existing cash, cash equivalents and short term-investments and the expected proceeds
from the PRV Transfer, timing and expansion of clinical trials, the number of U.S. patients with HET obesity or SRC1 or SH2B1
deficiency obesity who may be responsive to setmelanotide, prevalence estimates, regulatory plans, and future development for
the treatment of Alstr&#246;m syndrome. Statements using words such as &#8220;expect&#8221;, &#8220;anticipate&#8221;, &#8220;believe&#8221;,
 &#8220;may&#8221;, &#8220;will&#8221; and similar terms are also forward-looking statements. Such statements are subject to numerous
risks and uncertainties, including, but not limited to, the impact of our ability to enroll patients in clinical trials, the design
and outcome of clinical trials, the impact of competition, the ability to achieve or obtain necessary regulatory approvals, risks
associated with data analysis and reporting, our liquidity and expenses, the impact of the COVID-19 pandemic on our business and
operations, including our preclinical studies, clinical trials and commercialization prospects, and general economic conditions,
and the other important factors discussed under the caption &#8220;Risk Factors&#8221; in our Quarterly Report on Form 10-Q for
the quarterly period ended September 30, 2020 and our other filings with the Securities and Exchange Commission. Except as required
by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this Current Report or
to update them to reflect events or circumstances occurring after the date of this Current Report, whether as a result of new
information, future developments or otherwise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
<td style="vertical-align: top">&#160;</td>
<td colspan="2" style="vertical-align: bottom"><b>RHYTHM PHARMACEUTICALS, INC.</b></td></tr>
<tr>
<td style="vertical-align: top">&#160;</td>
<td colspan="2" style="vertical-align: bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top; width: 50%">Date:  February 3, 2021</td>
<td style="vertical-align: bottom; width: 4%">By:</td>
<td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 46%">/s/ Hunter Smith &#160;</td></tr>
<tr>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: bottom; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Name:&#160;&#160;&#160;&#160;</span></td>
<td style="vertical-align: bottom; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Hunter
Smith</span></td></tr>
<tr>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: bottom; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Title:</span></td>
<td style="vertical-align: bottom; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Chief
Financial Officer</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 8; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6La5OFN2dDhVxiowh3hYXpbg1I60/eyTf0m5DDIGQnPPlCDEQG1rrEhnOyyyFHKu6VA4hwysymgt6R7LdxeBnhjdtHSvjuvUHJuQZ9MxkOL74e+d8aotFDHIaynkYSZDzOJrBYi+CVk/IXHWBxmlVgjIFHJlq1ugUN/2HXL3JUNV0SSdkq8nEMBrKXv5AJEcRHOipXsR3C2maiGDQVSA2TI+6jXlYRxWsSqx8lu3Rfwdf3EdJFg== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>2
<FILENAME>rytm-20210202.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaeHGbOdzZR+SYkxtmB7bZm63ywlcNPruicyw1lmYYQF -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:rytm="http://rhythmtx.com/20210202" elementFormDefault="qualified" targetNamespace="http://rhythmtx.com/20210202">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://rhythmtx.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="rytm-20210202_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="rytm-20210202_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>3
<FILENAME>rytm-20210202_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>4
<FILENAME>rytm-20210202_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://rhythmtx.com/role/Cover" xlink:href="rytm-20210202.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://rhythmtx.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>5
<FILENAME>tm213890d3_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="rytm-20210202.xsd" xlink:type="simple"/>
    <context id="From2021-02-03to2021-02-03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649904</identifier>
        </entity>
        <period>
            <startDate>2021-02-03</startDate>
            <endDate>2021-02-03</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-02-03to2021-02-03">0001649904</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-02-03to2021-02-03">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2021-02-03to2021-02-03">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2021-02-03to2021-02-03">2021-02-03</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2021-02-03to2021-02-03">RHYTHM PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-02-03to2021-02-03">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2021-02-03to2021-02-03">001-38223</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-02-03to2021-02-03">46-2159271</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-02-03to2021-02-03">222 Berkeley Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2021-02-03to2021-02-03">12th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2021-02-03to2021-02-03">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-02-03to2021-02-03">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-02-03to2021-02-03">02116</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-02-03to2021-02-03">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-02-03to2021-02-03">264-4280</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2021-02-03to2021-02-03">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2021-02-03to2021-02-03">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2021-02-03to2021-02-03">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2021-02-03to2021-02-03">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2021-02-03to2021-02-03">Common     Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-02-03to2021-02-03">RYTM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-02-03to2021-02-03">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-02-03to2021-02-03">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288998974312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Feb. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb.  03,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">RHYTHM
PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001649904<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-2159271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">222
Berkeley Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">12th
Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">264-4280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RYTM<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>7
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ 2(5#4@=!36*!
ML0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    " !(A4-23NRC6.X    K @  $0              @ &O    9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    " !(A4-2F5R<(Q &  "<)P  $P
M        @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( $B%
M0U*M/>M45P0  -L0   8              " @0T(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    " !(A4-2@ZFE ]0!   R!@  #0
M        @ &:#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( $B%0U*7BKL<
MP    !,"   +              "  9D.  !?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( $B%0U*JQ"(6,P$  "("   /              "  8(/  !X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    " !(A4-2)!Z;HJT   #X 0  &@
M    @ 'B$   >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" !(A4-299!YDAD!  #/ P  $P              @ ''$0  6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     "0 ) #X"   1$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm213890d3_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rhythmtx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm213890d3_8k.htm">tm213890d3_8k.htm</File>
    <File>rytm-20210202.xsd</File>
    <File>rytm-20210202_lab.xml</File>
    <File>rytm-20210202_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>12
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm213890d3_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "tm213890d3_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "rytm-20210202_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rytm-20210202_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "rytm-20210202.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "rytm",
   "nsuri": "http://rhythmtx.com/20210202",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm213890d3_8k.htm",
      "contextRef": "From2021-02-03to2021-02-03",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://rhythmtx.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm213890d3_8k.htm",
      "contextRef": "From2021-02-03to2021-02-03",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r9",
      "r11",
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://rhythmtx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r10": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r11": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r12": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r13": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r14": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r15": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r16": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>13
<FILENAME>0001104659-21-011590-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-21-011590-xbrl.zip
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M!ME PHCAB.W'F5LII&2!_);F]Y;W2X\,0=)G#?O^6XZB=LXY66PLR;#EV J
M^>OY:8Y6,I610ZSTECY+;G[U-K*-<PDD\9K*VAPP(B(D4E-3I O-GEJGVM+O
M%K8!=A_E /=?')FAP;Y'-A3"_N-9NU9_\9!9@[CS#LF>5[NH:8XKI 9\K1VW
M3<ETOG<%3J2V4.P3S'G0AJ!7,>.D-%'^W.D^)N8WL)^)G'> B:VSNLB%VD2R
M"SAG[VI@Z^3?< W)_H5$ES"M\L@;W:S_31QN)]$ZP,_2"_>U=*V0RP6'W(QK
M2?%NI;+(O$F)ME;JME:\VAO-'&;D8!=+Q8=%Q+6<[E^UB\3\X2WULOHALE.I
MY*2T3.RGR=L<'%JRZSXVUVO3327-\@]02P,$%     @ 2(5#4I56":S^"@
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M(0Z!%W14T/A)12$=5MX_\\C3-TZW+,,BG_\N;*T4H'/+#V"SR8TA"H@7NS.
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M!)]FD&5[8*;'6';/(,1SQG038!ND(40J^Y/TADD4-%+T$EQ4)&')!BI:BQ6
MR$3II4&7:ONX8^DL7/5^/$DH=U2Q.@]*QGGSYI1^YDY,/\$2F)?:EPE5T]=Z
M%$Z-^N@/.5+H;6M7<2E+1L&*VIB7U":M('-?)S2&A@A\A:H7O-!)_4P!(Q+2
M6C"2$&\\;@/GCM$OZD]J=K:R2V(X3]:PY9R0YL@B'P7"-O]T(6"T_JP94I_
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M\![;HV105S(+">&XW %3K#'_N .+3/!]NG;43E72 1LNOO;;$:EW1R:##ED
M:O+L<=/*I*J08/HS*:)MHW;#.GJ.>DVB1#>$0\$(+G>ZI"IHFOMHSC<(!^@W
MRF=89 D5Q.<"T,=4B&,LKT+=W)B?^Z18+I<X,9LG[N4@IP7@J67@%4K &V<2
M;RSV(W75A"1">@4V<B[1M<5_Z@<-(& %.F]C6LJ(R=<0^70-/$A;V\ZMI,7X
M/L5Z9UX!JZ=R&[SJQYMZP>5[C)^'M9)'2;W-:5[!0AS #")=^V327],; 3'
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MV"1;8NH06LC =X!1X,WG%B#*N>/YA"=8&QALS@Y?&:(()5"$:J&87>AF+T+
M9FN"D?ZBT8CF1V&JT@E(!)^C58S#!?GQ*VAYP<A$0@/K_*3Q$>&D=F',;-54
M+#F[U:8+BJ'EP.HZEC9)TIA\)+XB[:',R6[RG9 U/%3>[IQ?XK^U]>5*1O'(
MKX#B2TSW  :/?%H)KS+&[+LR4B3Z%W#+?#*\PHFST'M7"D);E>)$O863L%L
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MK+'VR5ZN\52NU.09%1&B_5 EX3$V,'M[-.D5MT94JV::GX-#Q.Z!1/Y906O
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M;2TR,#(Q,#(P,BYX<V102P$"% ,4    " !(A4-2E58)K/X*  #@AP  %0
M            @ %N P  <GET;2TR,#(Q,#(P,E]L86(N>&UL4$L! A0#%
M  @ 2(5#4A1!+(E7!P  -5D  !4              ( !GPX  ')Y=&TM,C R
M,3 R,#)?<')E+GAM;%!+ 0(4 Q0    ( $B%0U(.0,)[E#4  $,K 0 1
M          "  2D6  !T;3(Q,S@Y,&0S7SAK+FAT;5!+!08     !  $  0!
(  #L2P     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
